Related Experiment Video
Updated: Aug 9, 2026

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
Published on: August 12, 2020
Biomarker-guided antibiotic duration strategies using C-reactive protein and/or procalcitonin for neonatal sepsis: a
Aditya Hemendra Bhatt1, Ankur Patel2, Praful Bhambharoliya2
1Department of Neonatology, Pramukhswami Medical College, Bhaikaka University, Karamsad, Gujarat, 388325, India.
Insights
Using biomarkers like C-reactive protein (CRP) and procalcitonin (PCT) to guide antibiotic duration in neonatal sepsis can safely reduce antibiotic exposure. This approach lowers the average treatment length without increasing risks of treatment failure or death.
Area of Science:
- Neonatal Medicine
- Infectious Diseases
- Biomarkers
Background:
- Prolonged antibiotic use in neonates is linked to adverse outcomes and antimicrobial resistance.
- Current neonatal sepsis protocols for antibiotic discontinuation are inconsistent.
- Biomarkers like CRP and PCT show potential for guiding treatment duration.
Purpose of the Study:
- To review evidence on using C-reactive protein (CRP) and/or procalcitonin (PCT) guided strategies for antibiotic duration in neonatal sepsis.
- To summarize the impact of these biomarker-guided strategies on antibiotic exposure and patient safety.
Main Methods:
- A systematic search of major databases (PubMed/MEDLINE, Embase, Web of Science, Cochrane Library) was conducted.
- Studies published up to December 2023, involving neonates (0-28 days) with sepsis, using serial CRP and/or PCT for antibiotic discontinuation were included.
- Data were screened and charted by two independent reviewers following Joanna Briggs Institute and PRISMA-ScR guidelines.
Main Results:
- Fifteen studies (4755 neonates) were included, evaluating CRP, PCT, or combined biomarker-guided strategies.
- Biomarker-guided care reduced mean antibiotic duration by 2.8 days (38.6%), from 7.3 to 4.5 days.
- No significant increase in treatment failure or mortality was observed with biomarker-guided discontinuation.
Conclusions:
- CRP- and/or PCT-guided strategies can effectively reduce antibiotic exposure in neonatal sepsis.
- These approaches appear safe, without increasing treatment failure or mortality.
- Standardized protocols and further research on cost-effectiveness and resistance are recommended, especially for preterm infants and in resource-limited settings.
Abstract:
Prolonged empirical antibiotic exposure in neonates is associated with adverse outcomes and antimicrobial resistance. Serial C-reactive protein (CRP) and procalcitonin (PCT) measurements may support earlier discontinuation, but neonatal protocols remain heterogeneous. To map evidence on CRP- and/or PCT-guided antibiotic-duration strategies in neonatal sepsis and summarize their effects on antibiotic exposure and safety. Following Joanna Briggs Institute guidance and PRISMA-ScR, PubMed/MEDLINE, Embase, Web of Science and the Cochrane Library were searched from inception to December 2023. Peer-reviewed English-language studies of neonates aged 0-28 days with suspected, probable or culture-proven early- or late-onset sepsis were included when serial CRP and/or PCT formed part of an explicit antibiotic-stopping strategy. Two reviewers independently screened records and charted study characteristics, protocols and outcomes. Fifteen studies involving 4755 neonates were included: five randomized trials, six cohort studies, two prospective observational studies and two systematic reviews with meta-analyses. Seven studies evaluated CRP-guided discontinuation, six evaluated PCT-guided strategies and four used combined approaches. Biomarker-guided care reduced mean antibiotic duration from 7.3 to 4.5 days, a mean reduction of 2.8 days (38.6%). Reductions were directionally consistent and appeared greater in early-onset than late-onset sepsis. Thirteen studies reported treatment failure and 14 reported mortality; neither outcome showed an apparent increase with biomarker-guided discontinuation. Antimicrobial-resistance, ecological and cost outcomes were infrequently reported. CRP- and/or PCT-guided stopping strategies may reduce antibiotic exposure in neonatal sepsis without an apparent increase in treatment failure or mortality. Standardized protocols and further implementation, cost-effectiveness and resistance-focused research are needed, particularly in resource-limited settings and extremely preterm infants.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Pneumonia III: Complications and Assessment
